Exploring Chemoimmunotherapy In Tnbc The Keynote 355 Trial
Exploring Chemoimmunotherapy In Tnbc The Keynote 355 Trial reveals several interesting facts.
- Heather McArthur, MD, MPH, of Cedars-Sinai Medical Center, Los Angeles, CA, outlines the findings from the
- ... discusses the data from the phase 3
- Javier Cortés, MD, PhD, Ramon y Cajal University Hospital, Madrid, Spain, discusses the
- During a discussion on
- Dr Javier Cortés speaks to ecancer online about the
In-Depth Information on Chemoimmunotherapy In Tnbc The Keynote 355 Trial
Including Previously, the Sara Tolaney, MD, MPH, Dana Farber Cancer Institute, Boston, MA, outlines the role of immunotherapy in Hope Rugo, MD, FASCO, University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San ...
Serafin Morales, PhD, of the University Hospital Arnau de Vilanova, Lleida, Spain, discusses the use of both immunotherapy and ...
Stay tuned for more updates related to Chemoimmunotherapy In Tnbc The Keynote 355 Trial.
